Oncologix Tech, Inc.
OCLG · OTC
11/30/2022 | 8/31/2022 | 11/30/2017 | 8/31/2017 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | -0.00 |
| FCF Yield | -0.56% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | -178.14 | 0.00 | 0.00 | 0.00 |
| Quality | ||||
| ROIC | -387.01% | 0.00% | 0.00% | 0.00% |
| Gross Margin | 0.00% | 0.00% | 23.28% | 14.59% |
| Cash Conversion Ratio | 1.00 | – | 0.05 | 0.32 |
| Growth | ||||
| Revenue 3-Year CAGR | -23.40% | -17.77% | -16.54% | -12.89% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | -1.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage | 0.00 | 0.00 | -0.35 | -0.54 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |